Next Article in Journal
Plant Proteomic Research 3.0: Challenges and Perspectives
Next Article in Special Issue
HGF and TSG-6 Released by Mesenchymal Stem Cells Attenuate Colon Radiation-Induced Fibrosis
Previous Article in Journal
The Interplay between HGF/c-met Axis and Nox4 in BRAF Mutated Melanoma
Previous Article in Special Issue
Mesenchymal Stem Cells in Multiple Sclerosis: Recent Evidence from Pre-Clinical to Clinical Studies
Open AccessReview

Therapeutic Properties of Mesenchymal Stromal/Stem Cells: The Need of Cell Priming for Cell-Free Therapies in Regenerative Medicine

Research Department, IRCCS ISMETT (Istituto Mediterraneo per i Trapianti e Terapie ad alta Specializzazione), 90127 Palermo, Italy
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2021, 22(2), 763; https://0-doi-org.brum.beds.ac.uk/10.3390/ijms22020763
Received: 22 December 2020 / Revised: 10 January 2021 / Accepted: 12 January 2021 / Published: 14 January 2021
Mesenchymal stromal/stem cells (MSCs) are multipotent adult stem cells that support homeostasis during tissue regeneration. In the last decade, cell therapies based on the use of MSCs have emerged as a promising strategy in the field of regenerative medicine. Although these cells possess robust therapeutic properties that can be applied in the treatment of different diseases, variables in preclinical and clinical trials lead to inconsistent outcomes. MSC therapeutic effects result from the secretion of bioactive molecules affected by either local microenvironment or MSC culture conditions. Hence, MSC paracrine action is currently being explored in several clinical settings either using a conditioned medium (CM) or MSC-derived exosomes (EXOs), where these products modulate tissue responses in different types of injuries. In this scenario, MSC paracrine mechanisms provide a promising framework for enhancing MSC therapeutic benefits, where the composition of secretome can be modulated by priming of the MSCs. In this review, we examine the literature on the priming of MSCs as a tool to enhance their therapeutic properties applicable to the main processes involved in tissue regeneration, including the reduction of fibrosis, the immunomodulation, the stimulation of angiogenesis, and the stimulation of resident progenitor cells, thereby providing new insights for the therapeutic use of MSCs-derived products. View Full-Text
Keywords: Mesenchymal stromal/stem cells; priming; paracrine mechanism; cell-free therapies; regenerative medicine Mesenchymal stromal/stem cells; priming; paracrine mechanism; cell-free therapies; regenerative medicine
Show Figures

Figure 1

MDPI and ACS Style

Miceli, V.; Bulati, M.; Iannolo, G.; Zito, G.; Gallo, A.; Conaldi, P.G. Therapeutic Properties of Mesenchymal Stromal/Stem Cells: The Need of Cell Priming for Cell-Free Therapies in Regenerative Medicine. Int. J. Mol. Sci. 2021, 22, 763. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms22020763

AMA Style

Miceli V, Bulati M, Iannolo G, Zito G, Gallo A, Conaldi PG. Therapeutic Properties of Mesenchymal Stromal/Stem Cells: The Need of Cell Priming for Cell-Free Therapies in Regenerative Medicine. International Journal of Molecular Sciences. 2021; 22(2):763. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms22020763

Chicago/Turabian Style

Miceli, Vitale; Bulati, Matteo; Iannolo, Gioacchin; Zito, Giovanni; Gallo, Alessia; Conaldi, Pier G. 2021. "Therapeutic Properties of Mesenchymal Stromal/Stem Cells: The Need of Cell Priming for Cell-Free Therapies in Regenerative Medicine" Int. J. Mol. Sci. 22, no. 2: 763. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms22020763

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop